Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: Clinical evidence for cross-resistance?

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2943-2947

  Mezynski, J ^a   Pezaro, C ^a   Bianchini, D ^a   Zivi, A ^a   Sandhu, S ^a   Thompson, E ^a   Hunt, J ^a   Sheridan, E ^a   Baikady, B ^a   Sarvadikar, A ^a   Maier, G ^a   Reid, A H M ^a   Mulick Cassidy, A ^a   Olmos, D ^a   Attard, G ^a   deBono, J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor; Castration resistant prostate cancer; Docetaxel; Response rate

Indexed keywords

EID: 84866909021     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds119     Document Type: Article

References (21)

1. Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England. London: Office for National Statistics 2010. MB1: no 39 ed.
2. Statistical Bulletin: Death Registrations by Cause in England and Wales, 2009. London: Office for National Stastitics 2010.
3. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
4. Kraus LA, Samuel SK, Schmid SM et al. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 2003; 21: 259-268.
5. Jiang J, Huang H. Targeting the androgen receptor by Taxol in castration-resistant prostate cancer. Mol Cell Pharmacol 2010; 2: 1-5.
6. Zhu ML, Horbinski CM, Garzotto M et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70: 7992-8002.
7. Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-6029.
8. Gan L, Chen S, Wang Y et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69: 8386-8394.
9. Kuroda K, Liu H, Kim S et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69: 1579-1585.
10. Attard G, Cooper CS, De Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break?. Cancer Cell 2009; 16: 458-462.
11. Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448.
12. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
13. Scher HI, Heller G, Molina A et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus prednisone (P) post docetaxel. J Clin Oncol 2011; 29 (Suppl) (Abstr LBA4517).
14. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
15. Ryan CJ, Shah S, Efstathiou E et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17: 4854-4861.
16. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501.
17. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
18. Armstrong AJ, Tannock IF, de Wit R et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-525.
19. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
20. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.